Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Trial ID or NCT#

NCT01818596

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.

Official Title

A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Philip Grant
Philip Grant
Positive care doctor, Infectious diseases doctor
Clinical Associate Professor, Medicine - Infectious Diseases
Andrew Zolopa

Contact us to find out if this trial is right for you.

Contact

Debbie Slamowitz
(650) 723-2804

View on ClinicalTrials.gov